Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
暂无分享,去创建一个
He Huang | Yanmin Zhao | X. Lai | Yi Luo | Jimin Shi | J. Yu | Yamin Tan | Li-zhen Liu | H. Fu | Mingming Zhang | Jian Yu | Hengwei Wu
[1] He Huang,et al. Ruxolitinib combined with etanercept induce a rapid response to corticosteroid‐refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi‐center prospective study , 2020, American journal of hematology.
[2] Y. Nieto,et al. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] M. Arbushites,et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial. , 2020, Blood.
[4] Haiyan Zhang. Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation. , 2020, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[5] J. Sierra,et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study , 2019, Bone Marrow Transplantation.
[6] K. Huelsman,et al. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] J. Dipersio,et al. Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease , 2018, Bone Marrow Transplantation.
[8] J. Dipersio,et al. The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] B. Blazar,et al. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. , 2017, The New England journal of medicine.
[10] B. Storer,et al. An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. , 2017, Blood.
[11] J. Ritz,et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] C. Lengerke,et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey , 2015, Leukemia.
[13] C. Recordati,et al. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects , 2015, Clinical Cancer Research.
[14] J. Pérez-Simón. Anti-common γ-chain antibody: one for all in GVHD. , 2015, Blood.
[15] Yoshiya Tanaka,et al. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro , 2014, Annals of the rheumatic diseases.
[16] J. Ritz,et al. Current issues in chronic graft-versus-host disease. , 2014, Blood.
[17] S. Held,et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. , 2013, Blood.
[18] J. Dipersio,et al. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD. , 2012, Blood.
[19] J. Ritz,et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. , 2012, Blood.
[20] M. Mohty,et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] E. Holler,et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] M. Nakahira,et al. Differential requirements for JAK2 and TYK2 in T cell proliferation and IFN‐γ production induced by IL‐12 alone or together with IL‐18 , 2003, European journal of immunology.